Advances in the understanding of the molecular biology of ER+ breast cancer led to a revolution in this field with the development of a variety of therapeutic agents that are now being used in routine clinical care in patients with metastatic disease such as CDK4/6, PI3K, and mTOR inhibitors (1). The gene discussed is MTOR; the disease is breast carcinoma.